Collegium's Strong Financial Performance in Q3 2025
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) has officially reported a remarkable third quarter of 2025, showcasing record-breaking financial results. The company generated net revenue of $209.4 million, marking a distinguished 31% increase compared to the same quarter last year. This impressive performance was driven by the continued success of their medication portfolio and a robust demand for Jornay PM.
Jornay PM Drives Revenue Growth
Highlights from the Q3 2025 Report
A significant contributor to Collegium's growth was the net revenue from Jornay PM, which reached $41.8 million in the third quarter. This represented a substantial year-over-year growth of 20% in prescriptions, demonstrating the effectiveness of Collegium's marketing strategies and the increasing recognition of Jornay PM's benefits among healthcare providers and patients.
Success in Pain Management Portfolio
Comprehensive Revenue Analysis
Collegium's pain management portfolio also showcased significant success, achieving record net revenue of $167.6 million—a year-over-year increase of 11%. All three core products in the pain portfolio contributed to the growth, underlining the company's effective approach to addressing the needs of patients suffering from pain conditions.
Updates on Financial Guidance and Future Outlook
Following the impressive Q3 results, Collegium has raised its full-year 2025 net revenue guidance to a range of $775 to $785 million, reflecting a positive outlook for the remainder of the year. Additionally, the company adjusted its EBITDA guidance to the range of $460 to $470 million. This strategic refinement indicates a solid commitment to financial discipline while pursuing growth opportunities.
Investor Relations and Upcoming Events
Collegium has maintained a healthy financial position, ending the quarter with cash, cash equivalents, and marketable securities totaling $285.9 million. The company is actively preparing for several significant upcoming investor conferences, including noteworthy events where they will share insights about their strategies and product advancements.
Future Prospects and Patient Commitment
As we look toward the future, Collegium remains steadfast in its commitment to improving the lives of patients dealing with complex medical conditions. Through disciplined capital deployment and continued focus on robust product development, they are paving the way for sustained growth and strong shareholder value. The company anticipates leveraging its differentiated medications to make a profound impact on patients' lives in the coming years.
Frequently Asked Questions
What were Collegium's Q3 2025 net revenues?
Collegium reported net revenues of $209.4 million for Q3 2025, a 31% year-over-year increase.
How did Jornay PM perform in Q3 2025?
Jornay PM generated $41.8 million in net revenue and saw a 20% increase in prescriptions year-over-year.
What is the updated financial guidance for 2025?
Collegium raised its net revenue guidance to a range of $775 to $785 million and adjusted EBITDA guidance to $460 to $470 million.
What is the company's focus moving forward?
Collegium’s focus remains on enhancing patient care through its differentiated medication portfolio and driving growth through strategic initiatives.
Who can be contacted for investor inquiries?
For investor inquiries, Ian Karp, Head of Investor Relations at Collegium, can be contacted via email at ir@collegiumpharma.com.
